Amberstone Biosciences Secures $12 Million Series A Financing To Advance Immuno-Oncology Pipeline Of Tumor Microenvironment Activated Therapeutics

Amberstone Biosciences, an emerging biotherapeutics company with unique expertise in conditionally active immunotherapeutics, announced the completion of a $12 million Series A financing round. The funding was led by Viva BioInnovator, Co-win Ventures and Sinovation Ventures, with additional support from ChangRong Capital, Lifespan Investments and existing shareholders.

Recommended AI News: Swiss Crypto Bank Collaborates with MT4 to Introduce Optimal Trading Environment

Amberstone will use the proceeds from the financing to advance its highly differentiated tumor microenvironment activated therapeutic programs including bispecific antibodies and immunocytokines to the investigational new drug application (IND) enabling stage.

“We are tremendously grateful for the strong support from our new and existing investors,” said Amberstone Biosciences President and CEO, George Wu, PhD. “With our unique Tumor Microenvironment Activated Therapeutics (T-MATE™) programs, we aim to develop safer and more effective therapies to benefit cancer patients. The funding and broad expertise and resources in the field provided by our investors will take us another step closer to our mission.”

“Amberstone’s T-MATE therapeutic molecules enabled by its innovative single-cell discovery engine represents a real breakthrough in immune-oncology. We are thoroughly impressed by Amberstone team’s rich experience in the cancer biology space. Viva is excited to work with Amberstone and syndicate partners to support its mission to provide next-generation innovative treatment options to patients,” said Han Dai, PhD, Chief Innovation Officer of Viva Biotech and Head of Viva BioInnovator.

Recommended News : Predictions Series 2022: Interview with Param Kahlon, Chief Product Officer at UiPath

“T cell immunotherapy has encountered great challenges in the complex microenvironment of solid tumors. The T-MATE molecules discovered through Amberstone’s world-leading cross-disciplinary drug discovery engine will break through the bottleneck of traditional methods and bring new hope to the treatment of solid tumors. Co-win Ventures is thrilled to work with Amberstone’s team and co-investors to explore the next generation of immunotherapies in solid tumors,” said Xin Huang, MD/PhD, a managing partner of Co-win Ventures.

“The expertise and strengths of Amberstone core team synergize well with one another. We are optimistic with the company’s uncapped growth potential. Amberstone exemplifies our firm’s investment strategy and mission to support deep-tech innovative entrepreneurs and companies,” said Sinovation Ventures’ partner in healthcare, Mr. Peter Wu.

Recommended AI News: Sukna Ventures and Unifonic Close Their Successful Entrepreneurial Program with Demo Day Presentations 

[To share your insights with us, please write to sghosh@martechseries.com]